Nasdaq

CG Oncology Reports Promising BOND-003 Data: 75.5% Complete Response Rate for Cretostimogene in Bladder Cancer Treatment

Cretostimogene shows promising efficacy in bladder cancer treatment, with 75.5% complete response rate and sustained duration of over 28 months. CG Oncology, Inc. announced encouraging results from ...
Seeking Alpha

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway SCLC is aggressive and ...
Nasdaq

Lyell Immunopharma Reports Positive Clinical Data for LYL314 in Large B-Cell Lymphoma with 88% Overall Response Rate

Lyell Immunopharma, Inc. announced promising clinical data for its CAR T-cell therapy candidate LYL314, showing an 88% overall response rate and a 72% complete response rate in patients with relapsed ...
Healio

High-fiber diet could improve response to immunotherapy for patients with melanoma

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A high-fiber diet intervention produced “promising” response results for patients receiving immune ...
The American Journal of Managed Care

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Zongertinib shows a 71% response rate and 12.4 months median progression-free survival in HER2-mutated NSCLC, with minimal adverse events. Patient-reported outcomes indicate rapid improvement in ...
Morningstar

Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"

70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for ...